Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.‘s venture capital and emerging companies department distinguishes itself for its deep knowledge of the life sciences sector, assisting biotech and healthtech companies and their investors. The team regularly represents founders and a broad range of investors, including venture capital firms, family offices, hedge funds, and private equity sponsors. Co-leading the practice from New York, Daniel DeWolf, who is also chair of the technology industry group, regularly advises both high-growth companies and institutional investors, while Samuel Effron recently advised Cadurion Pharmaceuticals on its $260 million series B financing. Alexander Civetta contributes extensively to the practice and is considerably fluent in the software and biotech industries. Joshua Fox advises emerging companies on day-to-day operations, venture financings, and strategic exits.